PDS Planning Inc Cuts Stock Position in Sanofi (NASDAQ:SNY)

PDS Planning Inc lessened its stake in shares of Sanofi (NASDAQ:SNYFree Report) by 12.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 5,730 shares of the company’s stock after selling 832 shares during the quarter. PDS Planning Inc’s holdings in Sanofi were worth $285,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Clearbridge Investments LLC raised its position in Sanofi by 8.4% in the third quarter. Clearbridge Investments LLC now owns 184,630 shares of the company’s stock worth $9,904,000 after acquiring an additional 14,362 shares in the last quarter. Dynamic Advisor Solutions LLC purchased a new position in Sanofi in the fourth quarter worth $2,104,000. Soros Fund Management LLC purchased a new position in Sanofi in the third quarter worth $11,533,000. International Assets Investment Management LLC purchased a new position in shares of Sanofi in the fourth quarter valued at $4,704,000. Finally, Clear Street Markets LLC increased its position in shares of Sanofi by 352.8% in the third quarter. Clear Street Markets LLC now owns 130,183 shares of the company’s stock valued at $6,983,000 after buying an additional 101,430 shares in the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Analyst Ratings Changes

SNY has been the subject of a number of research analyst reports. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. TheStreet cut Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Finally, Morgan Stanley initiated coverage on Sanofi in a research note on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Sanofi has an average rating of “Hold” and a consensus target price of $55.00.

Check Out Our Latest Research Report on SNY

Sanofi Stock Performance

NASDAQ SNY opened at $47.69 on Wednesday. The firm has a market capitalization of $120.64 billion, a P/E ratio of 20.21, a P/E/G ratio of 1.65 and a beta of 0.61. Sanofi has a 1-year low of $42.63 and a 1-year high of $57.82. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. The business’s 50-day simple moving average is $47.58 and its 200-day simple moving average is $48.45.

Sanofi (NASDAQ:SNYGet Free Report) last released its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). The firm had revenue of $11.76 billion during the quarter, compared to analyst estimates of $13.02 billion. Sanofi had a net margin of 12.56% and a return on equity of 27.47%. Equities analysts predict that Sanofi will post 4.11 EPS for the current year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be issued a dividend of $1.478 per share. This is an increase from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. The ex-dividend date is Thursday, May 9th. Sanofi’s dividend payout ratio (DPR) is presently 58.47%.

Sanofi Company Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Further Reading

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYFree Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.